| Dr Elena A Rostapshova, MD | |
|
126 Missouri Ave, Mcxp-ccs-cr, Fort Leonard Wood, MO 65473-8952 | |
| (573) 596-0417 | |
| (573) 596-0524 |
| Full Name | Dr Elena A Rostapshova |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 126 Missouri Ave, Fort Leonard Wood, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255300711 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | D61723 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Elena A Rostapshova, MD 126 Missouri Ave, Mcxp-ccs-cr, Fort Leonard Wood, MO 65473-8952 Ph: (573) 596-0417 | Dr Elena A Rostapshova, MD 126 Missouri Ave, Mcxp-ccs-cr, Fort Leonard Wood, MO 65473-8952 Ph: (573) 596-0417 |
News Archive
NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.
GlaxoSmithKline plc [LSE/NYSE: GSK] announced that the U.S. Food and Drug Administration (FDA) has approved FLULAVAL® QUADRIVALENT (Influenza Virus Vaccine) for the active immunization of persons three years of age and older to help prevent disease caused by seasonal influenza (flu) virus subtypes A and B contained in the vaccine.
Vical Incorporated today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7® in patients with metastatic melanoma has completed the trial's fifth scheduled safety analysis and recommended that the trial continue per the protocol.
A molecule thought to play a key role in some inflammatory diseases can be switched off by two widely used medicines, new research has shown.
Aravive Biologics, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track Designation to AVB-S6-500 as a potential treatment for platinum-resistant recurrent ovarian cancer.
› Verified 5 days ago
Andrea Stephenson, Pediatrics Medicare: Medicare Enrolled Practice Location: 4430 Missouri Ave, Fort Leonard Wood, MO 65473 Phone: 808-735-9617 | |
Egberto Toro, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 126 Missouri Ave, Attn: Mcxp-ccs-cr (credentials), Fort Leonard Wood, MO 65473 Phone: 573-596-0417 Fax: 573-596-0524 | |
Erica Marie Grimm, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 4430 Missouri Ave, Fort Leonard Wood, MO 65473 Phone: 573-596-1766 | |
Dr. Roman Oleh Bilynsky, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 126 Missouri Avenue, Glwach - Attn: Credentials Office, Fort Leonard Wood, MO 65473 Phone: 573-596-0415 Fax: 573-596-0524 | |
Dr. Thomas E Ellwood, M.D Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 126 Missouri Ave, Mcxp-ccs-cr, Fort Leonard Wood, MO 65473 Phone: 573-596-0417 Fax: 573-596-0524 | |
Ms. Marie Grace Noah, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 4430 Missouri Ave, Fort Leonard Wood, MO 65473 Phone: 573-596-0417 |